CLINICAL TRIALS PROFILE FOR KYNMOBI
✉ Email this page to a colleague
All Clinical Trials for KYNMOBI
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT05529095 ↗ | Sublingual Apomorphine in Refractory Restless Legs Syndrome | Not yet recruiting | Sunovion | Phase 4 | 2022-09-01 | This is an open label, short placebo-controlled trial in Restless Legs Syndrome (RLS) patients inadequately treated with standard therapy. Investigators hypothesize that the study drug, sublingual apomorphine (Kynmobi), may improve RLS breakthrough symptoms. This study is designed to determine if sublingual apomorphine improves breakthrough symptoms in RLS patients, in addition to subjective responses. |
NCT05529095 ↗ | Sublingual Apomorphine in Refractory Restless Legs Syndrome | Not yet recruiting | William Ondo, MD | Phase 4 | 2022-09-01 | This is an open label, short placebo-controlled trial in Restless Legs Syndrome (RLS) patients inadequately treated with standard therapy. Investigators hypothesize that the study drug, sublingual apomorphine (Kynmobi), may improve RLS breakthrough symptoms. This study is designed to determine if sublingual apomorphine improves breakthrough symptoms in RLS patients, in addition to subjective responses. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for KYNMOBI
Condition Name
Clinical Trial Locations for KYNMOBI
Trials by Country
Clinical Trial Progress for KYNMOBI
Clinical Trial Phase
Clinical Trial Sponsors for KYNMOBI
Sponsor Name